[Frontiers in Bioscience 11, 1284-1288, May 1, 2006]

Stop Flow in abdominal and pelvic cancer relapses

Rosario Vincenzo Iaffaioli 1, Gaetano Facchini 2, Anna Tortoriello 3, Feliciano Crovella 4, Giovannni Romano 5, Roberta Formato 2, Michele Santangelo 6, Emiddio Barletta 7, Francesco Fiore 8, Vittorio Iaccarino 9, Bruno Memoli 10, Roberto D'Angelo 8, Pier Luigi Pilati 11, Riccardo Rossi 11, Stefano Guadagni 12, Marcello Deraco 13, Sandro Pignata 2, Bruno Daniele 6, Gerardo Rosati 14, Bruno Massidda 14, Giovanni Mantovani 15, Enrico Di Salvo 6, Nicola Marzano 16, Vincenzo Memeo 17, Valerio Parisi 18, Giorgio Mallarini 19, and Giuseppe Colucci 20

1 Med Onc B INT Naples and Cagliari University, 2 Med Onc B INT Naples, Italy, 3Med Onc Pozzuoli (NA) H., 5 Gen. Surg. Battipaglia (SA), 6 Surg Av H, 6 Exper Surg Fed. II° Univ. Naples, Italy, 7 Med Onc Benevento, 8 Rad INT Naples, 9Rad. Fed. II Univ. Naples, 10 Neph Fed. II Univ. Naples, Italy, 11 Gen. Surg. Padova Univ; 12 Gen Surg L'Aquila Univ, 13 Surg INT Milano, Italy, 14 Med Onc Potenza H., 15 Med. Onc. Cagliari Univ, 16 Onc S.Paolo Hospital Bari, 1 7I Surg Clin Bari Univ, 18 Surg C INT Naples, Italy, 19 Rad Cagliari University 2 0Med Onc Int Bari, Italy

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Materials and methods
4. Results
5. Discussion
6. Acknowledgment
7. References

1. ABSTRACT

To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR / 63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.